Survivorship in AML–a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Acute myeloid leukemia (AML) carries poor survival and high recurrence rate. We conducted a retrospective analysis of AML patients (N = 453) treated with chemotherapy only or chemotherapy + hematopoietic cell transplant (HCT) who maintained their first complete remission (CR) for ≥3 years. Prior comorbidities, new comorbidities, secondary malignancies, late relapse, and causes of death (COD) were documented. New comorbidities for chemotherapy only patients (n = 304) included renal disease (10%), and osteopenia/osteoporosis (38%) for HCT patients (n = 149). Incidence of hypertension was similar in the chemotherapy only cohort and chemotherapy + HCT cohort (14% vs 17%). Secondary malignancies occurred in 13%, commonly skin, prostate and breast cancers. Common COD included: secondary malignancy (4%), HCT complications (3%), and late relapses (5%). Overall, 12% had a late relapse. Median overall survival for chemotherapy only and HCT was 10.7 and 12.7 years, respectively. Long-term AML survivors need routine monitoring for comorbidities, secondary malignancies, and late relapses.

Original languageEnglish (US)
Pages (from-to)3120-3127
Number of pages8
JournalLeukemia and Lymphoma
Volume61
Issue number13
DOIs
StatePublished - 2020

Keywords

  • Acute myeloid leukemia
  • comorbidities
  • remission
  • survivorship

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Survivorship in AML–a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years'. Together they form a unique fingerprint.

Cite this